SERI在2020至2025年间在全球非学术眼科研究机构中排名第1位。 SERI ranked #1 globally among non-academic ophthalmology research institutions from 2020–2025.

新加坡眼研究所(SERI)根据2020年至2025年的研究成绩,在非学术机构中排名第1位,在全球眼科中排名第2位。 The Singapore Eye Research Institute (SERI) has been ranked #1 among non-academic institutions and #2 globally in ophthalmology by ScholarGPS, based on research performance from 2020 to 2025. 承认突显了SERI在眼病研究方面的领导作用,包括糖尿病视网膜病、青光眼病、近视和角膜病,以及发展了Vabysmo和Myopine等关键治疗方法以及FDA批准的EndoGlide等医疗设备。 The recognition highlights SERI’s leadership in eye disease research, including diabetic retinopathy, glaucoma, myopia, and corneal conditions, as well as its development of key treatments like Vabysmo and Myopine, and medical devices such as the FDA-approved EndoGlide. SERI在AI驱动诊断(包括SELENA+工具)方面的工作,以及在数字健康和医疗成像方面的创新,进一步凸显了它对促进眼科护理的全球影响。 SERI’s work in AI-driven diagnostics, including the SELENA+ tool, and innovations in digital health and medical imaging further underscore its global impact in advancing eye care.